Although it has been reported that bezafibrate influences carbohydrate metabolism, this
possibility has never been properly evaluated in a controlled clinical trial. In this study we …

The effects of bezafibrate 400 mg day− 1 or placebo administered for 3 months, were
compared in 36 patients with stable Type 1 diabetes and hypercholesterolaemia and/or …

To investigate whether the lowering of triglyceride levels has beneficial effects on glucose
metabolism, we studied 13 nondiabetic men with combined hyperlipidemia (phenotype IIB) …

Ninety-eight type 2 diabetic patients with hyperlipidaemia in stable metabolic control with
diet alone (41) or diet plus hypoglycaemic agents (57) were divided into two groups: group 1 …

Non-insuiin-dependent diabetes mellitus (NIDDM) is characterized by hyperglycemia
secondary to increased hepatic glucose output and impaired extrahepatic insulin sensitivity …

Background The hypoglycemic effect of bezafibrate is well established, but administration to
a large population of patients with diabetes has not been reported. We investigated glycemic …

To assess bezafibrate efficacy in a diabetic population a single-blind randomized study was
performed in 32 diet-resistant type IIb hyperlipidaemic non-insulin-dependent (NID) diabetic …

The clinical efficacy of bezafibrate was examined with special reference to glucose
metabolism in patients with type 2 diabetes mellitus (DM2). In protocol 1, 342 patients with …

Glucose intolerance or diabetes mellitus, hyperlipidemia, obesity and hypertension may
have a close interrelation based on insulin resistance. We selected 28 impaired glucose …

We examined cellular membrane fatty acid composition and insulin sensitivity in patients
with mild essential hypertension and hyperlipidemia, and investigated whether bezafibrate …